Cisplatin Infusion Duration
Cisplatin should be infused over 6 to 8 hours with adequate intravenous hydration and mannitol to minimize nephrotoxicity. This is the FDA-approved standard administration method 1.
Standard Administration Protocol
The FDA drug label explicitly states that cisplatin should be administered by slow intravenous infusion over 6 to 8 hours, not by rapid intravenous injection 1. The specific protocol includes:
- Pre-hydration: 1-2 liters of fluid infused for 8-12 hours before cisplatin
- Infusion: Cisplatin diluted in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g mannitol, infused over 6-8 hours
- Post-hydration: Adequate hydration and urinary output maintained for 24 hours after infusion 1
Context-Specific Variations
Intraperitoneal Cisplatin (Ovarian Cancer)
For IP administration in optimally debulked ovarian cancer, cisplatin 75-100 mg/m² is given on day 2 following IV paclitaxel, though the specific infusion duration for IP cisplatin is not detailed in the guidelines 2, 3.
Testicular Cancer Regimens
In combination regimens (BEP, EP, VIP), cisplatin 20 mg/m² is administered IV daily for 5 days, repeated every 21 days 4. While the exact infusion time isn't specified in these protocols, the standard 6-8 hour infusion principle applies.
Evidence on Shorter Infusion Times
Recent research suggests shorter infusions may be feasible:
- A 2025 study found 1-hour cisplatin infusions in the outpatient setting showed no difference in nephrotoxicity compared to 3-hour infusions when adequate hydration was maintained 5
- However, this contradicts earlier pharmacokinetic data showing that longer infusions (20 hours) result in lower peak concentrations and potentially less nephrotoxicity compared to 1-hour infusions 6
- An older study demonstrated that 8-hour infusions produced significantly fewer emesis episodes than 1-hour infusions 7
Critical Safety Considerations
The 6-8 hour infusion duration is specifically designed to reduce peak plasma concentrations, which correlate with both nephrotoxicity and ototoxicity 1. Key toxicity concerns include:
- Nephrotoxicity: Dose-limiting toxicity occurring in 28-36% of patients at 50 mg/m² 1
- Ototoxicity: Related to peak plasma concentrations; occurs in up to 31% of patients, with 40-60% prevalence in children 1
- Ototoxic effects may be related to peak plasma concentration, making infusion duration particularly important 1
Practical Pitfalls to Avoid
- Never use rapid IV injection - this is explicitly contraindicated 1
- Never use aluminum-containing needles or IV sets - aluminum reacts with cisplatin causing precipitation and loss of potency 1
- Do not dilute in 5% Dextrose alone - must use dextrose in saline 1
- If diluted solution is not used within 6 hours, protect from light 1
While emerging evidence suggests shorter infusions may be safe in select outpatient settings with rigorous hydration protocols, the FDA-approved standard of 6-8 hours remains the safest approach to minimize both nephrotoxicity and ototoxicity, particularly for doses ≥50 mg/m².